DRG Market Assessment reports

Treatment of moderate to severe cancer pain will continue to be dominated by opioid analgesics for the foreseeable future. However, with the widespread epidemic of opioid abuse and misuse in the…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following…

Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…

The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The…

Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-…

Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in…

Neuropathic pain (NP) is a prominent form of pain associated with a variety of diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, and multiple sclerosis. A…

Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…

Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…

A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…

Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…